Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program  SARASOTA, FLA., Aug.  18, 2026  (GLOBE NEWSWIRE) --

SILO

Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment

Silo gains Canadian patent allowance, strengthening SPC-15 IP moat and timelines

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program  SARASOTA, FLA., Aug.  18, 2026  (GLOBE NEWSWIRE) --</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Silo Pharma announced that Canada’s CIPO issued a Notice of Allowance for SPC-15, enhancing protection alongside a European patent and its Columbia University license. The milestone strengthens SPC-15&#039;s global IP moat and supports potential late-stage development and commercialization. Silo plans to leverage the FDA&#039;s 505(b)(2) pathway to shorten timelines and reduce costs, improving the program&#039;s value proposition.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Canada CIPO notices for SPC-15 patent; strengthens global IP moat. Part of Columbia University exclusive license for SPC-15.</li><li>European patent granted for SPC-15 core invention. Global protection expands the program&#039;s potential value.</li><li>FDA 505(b)(2) pathway could shorten SPC-15 timelines. Could reduce development costs.</li><li>QwikAgents AI subsidiary underscores Silo&#039;s diversified growth. Strategic leverage into tech markets alongside biopharma.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Silo Pharma, Inc. (SILO)</strong>: IP milestones for SPC-15 may enhance valuation and licensing opportunities.</li><li><strong>Columbia University (CU)</strong>: Licensee/partner; critical for global development and manufacturing of SPC-15.</li><li><strong>Canadian Intellectual Property Office (CIPO)</strong>: Issued Notice of Allowance; public patent office milestone with global implications.</li><li><strong>European Patent Office (EPO)</strong>: Granted European patent; expands protection and potential cross-border value.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>Industry News documenting IP milestones that bolster Silo&#039;s lead program SPC-15 and global footprint; supports longer-term value and potential licensing/leverage opportunities.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Canada patent allowance could unlock upside if mirrored by broader market protection.</li><li>European patent grant reinforces global protection and licensing upside.</li><li>505(b)(2) pathway may shorten SPC-15 timelines, reducing near-term risk.</li><li>QwikAgents AI subsidiary adds growth catalysts beyond biotech.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date: Aug 18, 2026.</li><li>Canada CIPO Notice of Allowance for SPC-15 patent.</li><li>Exclusive Canadian license with Columbia University for SPC-15.</li><li>European patent granted for SPC-15 core invention.</li><li>FDA 505(b)(2) regulatory pathway planned for SPC-15.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish for SPC-15; catalysts over 12–24 months include patent grants and FDA timing.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="center"><b><i>Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program</i></b></p>  <p><strong>SARASOTA, FLA., Aug.  18, 2026  (GLOBE NEWSWIRE) -- </strong>Silo Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/SILO">SILO</a>) ("Silo" or "the Company"), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent platform subsidiary, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, an intranasal 5-HT4 receptor agonist targeting post-traumatic stress disorder (PTSD) and other stress-induced psychiatric disorders. The Company has an exclusive license for the Canadian patent application as part of its broader license agreement with Columbia University to further develop, manufacture, and commercialize SPC-15 globally.</p>  <p>The allowed patent application, titled "Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress," covers methods of preventing or delaying stress-induced fear and depressive-like behavior and methods for inducing and/or enhancing stress resilience by administering selected serotonin 4 (5-HT4) receptor agonists prior to a stressor. Corresponding intellectual property has been granted or is advancing in multiple international markets, including a recently granted European patent covering the same core invention.</p>  <p>"The Canadian patent allowance adds to our momentum in securing broad international protection for SPC-15," said Eric Weisblum, Chief Executive Officer of Silo Pharma. "With corresponding claims receiving protection across multiple markets, we continue to strengthen the global IP position of SPC-15 and our broader therapeutic portfolio."</p>  <p>Silo intends to utilize the FDA’s streamlined 505(b)(2) regulatory pathway for SPC-15, which could shorten clinical timelines and reduce development costs</p>  <p><b>About Silo Pharma, Inc.</b></p>  <p><b>Silo Pharma</b> is a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for post-traumatic stress disorder (PTSD), SP-26 for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer’s disease. Silo’s research is conducted in collaboration with leading universities and laboratories. <a href="https://www.globenewswire.com/Tracker?data=MkgpHbf0CNkgxcBcXf8s56VZihS-6jjnMnMIkSHoAr09amNywc5iSVIbc-KiT5dZEFO8X86p9kGXkxIgVrMuy2aFL9M4uOmqqaVI-udnMl5vaEyUHZNdJTPdRP4BeDTBzY0VZEjHtO7D4JE2xOfWeYgcmjoSJQJQQTWRBaw8M9kYu9PugI3ETMB_j8rwtxb-dl99FlLltSkEOR_4B3dYKVNMrF6KdHtU4KWA2tTKBnBz6fKZ7468lr7R5xk8UUxK3pKty8vSMMluXxVPmp6t85lmG6X6IRmS8FaD77GW6fjJQSjG1KqUjzo6s3AzrpZzefDMHTeDlIxuG7taRW8vpi-SkXy1c5Xbfy1Lwtd-aZ9lR4qgXf-iVyfRHniJwcZXYLzm_ktlctLdvvfWfokVLcBymqdkBrpx0jzttUgmfSaRt5xfJt6SmN9WqNN7xPXuvrH7buZIVdAc0FfdkDceo_iizACuBKW9DbiX9mFUUiwtMUzMIgwElYBCDZHjK-YVKDb_2yDzxC29G7arES76ULmozHyUD3UV0NDfGx9uFvFdKcFzpQ-xOkzwLOTu5_d0U4bCuxLZHMufuAOBI_grZO0Gf8rGy0Fmw1oPgYDI3RT2lyUQXK9C5qAz9cL0P64cxj1IhSbfTGYf0ZMM-SEif_ahGrAg1jWQ-QQh8BFBppL8_tJSF6iRX5ScbB8PrLTC741b248ccaG0JUTIEdgadUXGWVhrpyrJ920g4ZrhQCmV0ggpmpdeD0yZicJEs7dTMCOGJ1mzuu9hoSMm-GfNfxjBn1Fm5ZhmzfYMyj2RJ_X7Czdgn03KCYOzeArvCofMaQdrEV8P1TXHdzFXCP97AqQSLJ8RwiawL8rF_HADDoUEKPJhq1vD6HLx8Ot6RN-7qG0-rJimNK8-EgV4vifoYE-rFHCCTRcKZb01lWabSNMD1HI0CEhroPUsPcbqY4-jAJgSIlkLQF4IcI8EMJ3FaScMmNdz8-giZHvpBdLuMPpYRjkzmNxhJsHmlCe0QpCh" rel="nofollow" target="_blank"><u>silopharma.com</u></a></p>  <p><b>QwikAgents</b>, Silo Pharma&#39;s wholly owned artificial intelligence subsidiary, is a managed AI agent platform that delivers dedicated autonomous agents for research, content generation, scheduling, and workflow automation each running in a persistent environment with proprietary smart-routing across multiple AI models. The subsidiary reflects Silo&#39;s strategy to expand into high-growth technology markets while continuing to advance its core biopharmaceutical pipeline. <a href="https://www.globenewswire.com/Tracker?data=e4TY0izYTa81DP4DY5WdzwSfGMEIgNvIni9EQANaJIuBZTqXCoa0KXURQREqKbhm51ogj3Utms0Wl5Eaxyb1IbCfrEp9Drv8uSOzeaY3ozzSzmre86mxmEjsSSO0V_M2KIQEF_a7oicuG6K7gKRPsG1n9JrjfPQXQT_aAAPDPFOACrLkHqgAJm74-lV0HEiYdq7QG1GGpSvcMcxnrzAk-1NAmB-AZfZkPCbV-4OFHOA=" rel="nofollow" target="_blank">qwikagents.com</a></p>  <p><b>Forward Looking Statements</b><br></br><br></br>This news release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words "could", "believe", "anticipate", "intend", "estimate", "expect", "may", "continue", "predict", "potential", and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.</p>  <p><b>Contact</b></p>  <p>(800) 705-0120<br></br><a href="https://www.globenewswire.com/Tracker?data=dZNO289dOT7GYjMh0GKyeDOdQsze9q0tWWoI5bYm719T_lrUgQqZDTKt6slM1jbgTPcVFySe2nGq1yjfby_G-129ywM1x-l2iuz4jLwtQzuPZ70ynh_6R_bmt0JfexaCJMqk_oXW9BRBBOKd7tS1mRB22wpItjrpdRb-187hPDND9YJzac0zFCPiqBsXJoMnjewq5jdwNKgkRIXGwrBLJJuDW-q4vJ69GEOodGBcmxFm7QBDf6e0fyWIJ129wvSLSMMtPpVrszRFTtjObwuqoY-rPiCoNA_HarOqkzzBFLpvXzDdSkHSOlkEwEGptbKSsSVw61wW9L59ek3WHrQ2TzJEtbCUvV7LvzE00B6s-tpxju6foG8toPV45W8ktO7oWvfAChJkeTpQjSXaNeXHsbLIByQfJzq8bGBX3uLEs9_5dOdFjdsR7POn74YDjddgC8zfJtDhFzGIddAE9FgIVKCJsaABG88kKRgWYOpTmvi01LXabgysxTdKHGWsw2kRCLsVMpdathMUZrgLz-jJbA==" rel="nofollow" target="_blank"><u>investors@silopharma.com</u></a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTgxMjI1MiM3NzgyNzAyIzUwMDA2OTMzOQ=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/MzY2Yzk5YWQtYzFmZi00MzA5LTk4N2YtMjlkNjRjOGM2NWNjLTUwMDA2OTMzOS0yMDI2LTA4LTE4LWVu/tiny/Silo-Pharma-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/3b635464-4382-4b8b-8175-39cc32e08050"><img src="https://ml.globenewswire.com/media/3b635464-4382-4b8b-8175-39cc32e08050/small/logo-png.png" border="0" width="150" height="73" alt="Primary Logo"></img></a></p>

Silo Pharma announced that Canada’s CIPO issued a Notice of Allowance for SPC-15, enhancing protection alongside a European patent and its Columbia University license. The milestone strengthens SPC-15's global IP moat and supports potential late-stage development and commercialization. Silo plans to leverage the FDA's 505(b)(2) pathway to shorten timelines and reduce costs, improving the program's value proposition.

News insight

Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment

AI summary

Sentiment rationale

Key facts

Industry News